The novel IKK2 inhibitor LY2409881 potently synergizes with histone deacetylase inhibitors in preclinical models of lymphoma through the downregulation of NF-κB.

@article{Deng2015TheNI,
  title={The novel IKK2 inhibitor LY2409881 potently synergizes with histone deacetylase inhibitors in preclinical models of lymphoma through the downregulation of NF-κB.},
  author={Changchun Deng and Mark Lipstein and Richard Rodriguez and Xavier O. Jirau Serrano and Christine M Mcintosh and W Y Tsai and Andrew S. Wasmuth and Susan Jaken and Owen A O'connor},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2015},
  volume={21 1},
  pages={134-45}
}
PURPOSE To evaluate the pharmacologic activity of a novel inhibitor of IκB kinase β (IKK2), LY2409881, in preclinical models of B- and T-cell lymphoma, as a single agent and in combination with histone deacetylase (HDAC) inhibitors. EXPERIMENTAL DESIGN The in vitro activity of LY2409881 was determined using an ATP-based growth inhibition assay and flow cytometric assay of apoptosis in lymphoma cell lines. The in vivo activity of LY2409881 was determined using SCID-beige xenograft mouse model… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 36 references

The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 modulates chronic active BCR signaling and induces tumor regression in relapsed/refractory ABC DLBCL [abstract

  • LM Staudt, K Dunleavy, JJ Buggy, E Hedrick, N Lucas, S Pittaluga
  • Proceedings of the 53rd ASH Annual Meeting and…
  • 2015
1 Excerpt

Similar Papers

Loading similar papers…